首页> 外国专利> blood sugar lowering bentseenisulfonyylivirtsa - integrated inventory of pollutant production.

blood sugar lowering bentseenisulfonyylivirtsa - integrated inventory of pollutant production.

机译:降低血糖bentseenisulfonyylivirtsa-污染物生产综合清单。

摘要

1,171,935. Benzenesulphonyl ureas. FARBWERKE HOECHST A.G. 1 Dec., 1966 [2 Dec., 1965], No. 53773/66. Heading C2C. The invention comprises compounds of formula wherein R is H, C 1-4 alkyl or phenyl-C 1-4 . alkyl; RSP1/SP is a C 2-8 alkyl, alkenyl or mercaptoalkyl group, a C 4-8 alkoxyalkyl, alkylmercaptoalkyl or alkylsulphinylalkyl group containing at least 2 carbon atoms in the alkylene part, phenyl - C 1-4 - alkyl, phenylcyclopropyl, cyclohexyl - C 1-4 - alkyl, cycloheptylmethyl, cycloheptylethyl, cyclooctylmethyl, an endoalkylenecyclohexyl, -cyclohexenyl, -cyclohexylmethyl or cyclohexenylmethyl group containing 1 or 2 carbon atoms in the endoalkylene part, (C 1-4 alkyl)-cyclohexyl, (C 1-4 alkoxy)-cyclohexyl, C 5-8 cycloalkyl, cyclohexenyl, cyclohexenylmethyl, or a C 4-5 O or C 4-5 S heterocyclic ring optionally containing 1 or 2 ethylenic double bonds and connected to the nitrogen atom either directly or via a CH 2 group: Y is a C 1-4 hydrocarbon chain; Z is C 5-6 aliphatic hydrocarbyl, or a phenyl group optionally substituted by a member selected from C 1-4 alkyl, C 1-4 alkoxy, CF 3 , Cl, Br and F; X is H (provided that Z is optionally substituted phenyl), halogen, C 1-4 alkyl, C 1-4 alkoxy, CF 3 or NO 2 ; and wherein the "phenylene " group is optionally substituted by one or more members selected from C 1-4 alkyl, C 1-4 alkoxy and halogen; and the physiologically tolerable salts of such compounds. These compounds are prepared by (a) reacting RSP1/SPNH 2 or a salt thereof with an appropriately substituted benzenesulphonyl-carbamic acid ester, - thiolcarbamic acid ester, -isocyanate, -urea, - semicarbazide, or -semicarbazone; or (b) reacting an RSP1/SP-substituted isocyanate, carbamic acid ester, thiolcarbamic acid ester, carbamic acid halide or urea with an appropriately substituted benzenesulphonamide; or (c) hydrolysing a correspondingly substituted benzenesulphonyl-isourea ether, -isourea ester, -isothiourea ether, -parabanic acid or -haloformic acid amidine; or (d) hydration of a correspondingly substituted benzenesulphonyl-carbodiimide; or (e) replacing S by O in a correspondingly substituted benzenesulphonyl-thiourea; or (f) by acylating a compound of formula RNH.Y.phenylene.SO 2 .NH.CO.NH.RSP1/SP. Variations of the above methods are also referred to. 4 - [#, - (2 - Phenoxy - benzamido) - ethyl]- benzene-sulphonamide is prepared by reacting 2- phenoxy-benzoyl chloride with 4-(#-aminoethyl)-benzenesulphonamide. N - {4 - [# - (2 - Phenoxy - benzamido) - ethyl]- benzenesulphonyl } - NSP1/SP - cyclohexyl - thiourea is prepared by reacting 4-[#-(2-phenoxy-benzamido) - ethyl] - benzenesulphonamide with cyclohexyl isothiocyanate, and is convertible with mercuric oxide, methanol and K 2 CO 3 into the corresponding isourea methyl ether. N - {4 - [# - (2 - phenoxy - benzamido) - ethyl]- benzenesulphonyl} - urea is prepared by reacting 4 - [# - (2 - phenoxy - benzamido) - ethyl]- benzenesulphonamide with potassium cyanate. N - {4 - [ - (2 - chloro - 5 - nitro - benzamido)- propyl] - benzenesulphonyl} - NSP1/SP - cyclohexylurea is prepared by reacting 2-chloro-5-nitrobenzoyl chloride with N-[4-(-amino-propyl)- benzenesulphonyl} - NSP1/SP - cyclohexyl - urea, the last-named compound being in turn prepared by hydrolysis of the corresponding -acetamidopropyl compound. N - {4 - [# - (2 - phenoxy - benzamido)- ethyl] - benzenesulphonyl} - NSP1/SP - (2,5 - endomethylene - cyclohexyl - methyl) - thiourea is prepared by reacting 4 - [# - (2 - phenoxybenzamido) - ethyl] - benzenesulphonamide with 2,5 - endomethylene - cyclohexyl - methyl isothiocyanate. N - {4 - [# - (2 - phenoxy - benzamido) - ethyl]- benzenesulphonyl} - NSP1/SP - cyclohexyl - isothiourea methyl ether is prepared from the corresponding thiourea by reaction with methyl iodide. The benzenesulphonyl-ureas of the invention and their physiologically tolerable salts are stated to possess hypoglemic action and may be made up with carriers into pharmaceutical compositions suitable for oral administration. The salts may be alkali metal or alkaline earth metal salts.
机译:1,171,935。苯磺酰脲。 FARBWERKE HOECHST A.G.,1966年12月1日[1965年12月2日],编号53773/66。标题C2C。本发明包括下式的化合物,其中R是H,C 1-4烷基或苯基-C 1-4。烷基; R 1 是亚烷基部分中至少包含2个碳原子的C 2-8烷基,烯基或巯基烷基,C 4-8烷氧基烷基,烷基巯基烷基或烷基亚磺酰基烷基,苯基-C 1-4 -烷基,苯基环丙基,环己基-C 1-4-烷基,环庚基甲基,环庚基乙基,环辛基甲基,内亚烷基环己基,-环己烯基,-环己基甲基或环己烯基甲基,在内亚烷基部分包含1或2个碳原子,(C 1-4烷基)-环己基,(C 1-4烷氧基)-环己基,C 5-8环烷基,环己烯基,环己烯基甲基或任选包含1个或2个烯键式双键并与氮原子相连的C 4-5 O或C 4-5 S杂环直接或通过CH 2基团的原子:Y是C 1-4烃链; Z为C 5-6脂族烃基,或任选地选自C 1-4烷基,C 1-4烷氧基,CF 3,Cl,Br和F中的一个取代的苯基; X为H(假设Z为任选取代的苯基),卤素,C 1-4烷基,C 1-4烷氧基,CF 3或NO 2;其中“亚苯基”任选地被一个或多个选自C 1-4烷基,C 1-4烷氧基和卤素的成员取代;以及此类化​​合物的生理耐受盐。这些化合物是通过(a)使R 1 NH 2或其盐与适当取代的苯磺酰基-氨基甲酸酯,-硫代氨基甲酸酯,-异氰酸酯,-脲,-氨基脲或-氨基脲(b)使RSP 1取代的异氰酸酯,氨基甲酸酯,硫代氨基甲酸酯,氨基甲酰卤或脲与适当取代的苯磺酰胺反应;或(c)水解相应取代的苯磺酰基-异脲醚,-异脲酯,-异硫脲醚,-对羟基苯甲酸酯或-卤代甲酸am; (d)水合相应取代的苯磺酰基-碳二亚胺; (e)在相应取代的苯磺酰基-硫脲中用O代替S;或(f)通过酰化式RNH.Y.亚苯基.SO 2 .NH.CO.NH.R 1 的化合物。还参考了上述方法的变型。通过使2-苯氧基-苯甲酰氯与4-(#-氨基乙基)-苯磺酰胺反应制备4-[#,-(2-苯氧基-苯甲酰氨基)-乙基]-苯磺酰胺。通过使4-[#-(2-苯氧基-苯甲酰胺基)反应制备N-{4-[#-(2--苯氧基-苯甲酰氨基)-乙基]-苯磺酰基}-N 1 -环己基-硫脲。 )-乙基]-苯磺酰胺与异硫氰酸环己酯,并可以与氧化汞,甲醇和K 2 CO 3转化为相应的异脲甲基醚。通过使4-[[-(2-苯氧基-苯甲酰氨基)-乙基]-苯磺酰胺与氰酸钾反应制备N-{4-[#-(2-苯氧基-苯甲酰氨基)-乙基]-苯磺酰基}-脲。 N-{4--[-(2-氯-5-硝基-苯甲酰胺基)-丙基]-苯磺酰基}-N 1 -环己基脲是使2-氯-5-硝基苯甲酰氯与N反应制得的-[4-(-氨基-丙基)-苯磺酰基} -N 1 -环己基-脲,最后的化合物是通过水解相应的-乙酰氨基丙基化合物而制备的。 N-{4--[#-​​(2--苯氧基-苯甲酰氨基)-乙基]-苯磺酰基}-N 1 -(2,5--内亚甲基-环己基-甲基)-硫脲是由4反应制得的-[#-(2-苯氧基苯甲酰胺基)-乙基]-苯磺酰胺与2,5-内亚甲基-环己基-异硫氰酸甲酯。由相应的硫脲与甲基碘反应,制得N-{4--[#-​​(2-苯氧基-苯甲酰氨基)-乙基]-苯磺酰基}-N 1 -环己基-异硫脲甲基醚。据称,本发明的苯磺酰基-脲及其生理上可接受的盐具有降血脂作用,并且可以与载体一起制成适合口服的药物组合物。该盐可以是碱金属或碱土金属盐。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号